Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Teijin Aims at \200 Bil. Drug Sales via M&As, JV
August 26, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 26, 2002
- BULLETIN -3-
August 26, 2002
- Alliances Make Shionogi Accelerate Pharmacogenomic Research
August 26, 2002
- Banyu to Develop Once-a-week Version for Fosamac
August 26, 2002
- Korosho Calls For Self-inspections of Reusable Medical Devices
August 26, 2002
- Kuraya Sanseido to Completely Acquire Ushioda Sangokudo
August 26, 2002
- RIKEN Clarifies Repair Mechanism of DNA Lesions
August 26, 2002
- Goodman Acquires LightLab with OCT Technology
August 26, 2002
- Suzuken Transfers Nursing Care Business in Hokkaido to Medca Japan
August 26, 2002
- Osteoporosis Treatment Should Aim at Fracture Prevention, Improvement of QOL: Society Meeting
August 26, 2002
- Daiichi to Place Priority on Expansion of US Product Line
August 26, 2002
- BUSINESS NEWS IN BRIEF
August 26, 2002
- PRESS SEMINAR
August 26, 2002
- BULLETIN -1-
August 26, 2002
- WEBSITE NEWS
August 26, 2002
- GCP Revision to Follow PAL Amendment
August 26, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 26, 2002
- Outline of New NDA Reviewing Institution Revealed
August 26, 2002
- Large Product Line, Reasonable Prices in Drug Stores Are Appreciated: Survey
August 26, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…